Resources

Causaly Announces Agentic AI for Scientific Discovery

New AI agents in Causaly Discover empower scientists to answer complex biomedical questions faster and more accurately across a broader range of sources

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Causaly announces ISO 27001 certification

We are proud to announce a major milestone for Causaly: successfully passing ISO 27001 certification.

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

Covid-19: Causaly partners with UCL to accelerate coronavirus research

At Causaly we’re excited to announce a new partnership with University College London (UCL) to help accelerate research into the pandemic.

Causaly raises $5m in Series A round led by Pentech Ventures

Causaly, the AI company that is teaching computers to read, understand and interpret all biomedical knowledge ever published, is pleased to announce its series A funding round, which saw new and existing investors commit $4.8m into the company. Pentech Ventures led the round together with EBRD Venture Capital, with participation from existing investors Marathon Venture Capital as well as existing angel investors.

ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform